Interlake-Eastern Regional Health Authority

Quadrivalent Inactivated INFLUENZA VACCINE 2017-2018

(A/Michigan/45/2015 (H1N1) pdm09-like virus; A/Hong Kong/4801/2014 (H3N2)-like virus; B/Brisbane/60/2008-like virus; B/Phuket/3073/2013-like virus)

Indications	Contraindications to Flu Vaccine*	Common side effects
All Manitobans including: • Seniors ≥ 65 years old • Children six to 59 months • PCH/LTC residents • Anyone with chronic health issues • Morbidly obese people • Pregnant women • Health care workers & first responders • Caregivers of children ≤5 yrs • Indigenous peoples • Household contacts of those listed above	• History of anaphylaxis to previous flu vaccination • History of Guillain-Barre syndrome within 6 weeks of a previous flu vaccination • Infants < 6 months of age • History of anaphylaxis to any vaccine component listed in the following product: • **Fluzone® vaccine:** egg protein*, formaldehyde, Triton® X-100, sucrose, thimerosal (*multidose presentation only*). Fluzone® is latex-free • **Flulaval® vaccine:** egg protein*, sodium deoxycholate, ethanol, formaldehyde, sucrose, α-tocopheryl hydrogen succinate, polysorbate 80, thimerosal. • ***(FluMist® vaccine:** see reverse side)*	• Injection-site reactions such as pain, redness, swelling. • Systemic reactions such as headache, fatigue, sore muscles/joints, irritability (in children).

VACCINE DOSE

Age group	Dosage	# of doses	Route
6 months to < 9 years	0.5 mL	1 or 2**	IM
≥ 9 years	0.5 mL	1	IM

* NACI has concluded that **egg allergic individuals without other contraindications to the vaccine may be vaccinated against influenza using inactivated QIV or LAIV** without prior influenza vaccine skin test and with the full dose. The vaccine may be given in any setting where vaccines are routinely administered. (NACI Statement 2017-2018). Vaccine recipients should be kept under observation for 30 minutes when there is a specific concern about possible vaccine allergy (CIG).

** Two doses administered at least one month apart are recommended for children < 9 years of age receiving seasonal influenza vaccine for the first time.

PNEUMOCOCCAL 23 VACCINE 2017

Indications	Contraindications to Pneumovax 23® Vaccine	Common side effects
• **All seniors ≥ 65 years of age** • **All residents of PCHs** • **Homeless individuals** • **Illicit drug users** • **All persons ≥ 2 years of age with:** • Anatomic or functional asplenia • Hemoglobinopathy • Weakened immune system r/t disease or therapy • Kidney, heart, liver or lung disease • Alcoholism • Diabetes • Cerebrospinal fluid (CSF) leak • Solid organ or stem cell transplant	• History of anaphylaxis to a previous dose of a pneumococcal vaccine • **Pneumovax 23® vaccine:** history of anaphylaxis to any component of Pneumovax 23 (ie/ phenol) • Do not administer Pneumovax23 and ZOSTAVAX™ vaccine at the same time due to the possibility of an inferior immune response to ZOSTAVAX™. Separate these vaccines by 4 weeks. • The container closure system of Pneumovax 23 is latex-free.	• Injection site reactions such as pain, redness, swelling, warmth • Systemic reactions such as fatigue, sore muscles, headache.

Dosage for Adults and Children ≥ 2 years of age: 1 dose 0.5 mL IM or SC

Routine re-immunization of healthy individuals with Pneu-P-23 vaccine is not recommended. However, one lifetime booster is recommended 5 years after the initial dose for those at highest risk of invasive pneumococcal disease (i.e. asplenia, hemoglobinopathy, liver or kidney disease, HIV infection and immunosuppression). Because there are insufficient data to recommend repeated administration of Pneu-P-23 vaccine, re-vaccination following a second dose is not routinely recommended. *(CIG). The public health program follows the provincial & national guidelines & will not be administering more doses than currently recommended.*

FLUMIST®

Indications:

- 2 – 17 years of age

Contraindications:

- **Children < 2 years of age**
- Pregnant females
- Children with an immune system weakened by disease or medical treatment
- History of severe allergic (anaphylactic) reaction to a previous dose of any type of flu vaccine or any component of FluMist® (**gentamycin** [*tobramycin, neomycin, streptomycin, kanamycin, amikacin*]**, gelatin hydrolysate, sucrose, arginine, monosodium glutamate)**
- Those with severe asthma or active wheezing in the last 7 days
- Health care workers working with immunocompromised individuals.
- Those ≤ 17 years of age who are on long term aspirin treatment in the last 4 weeks
- Those with a history of Guillain Barre Syndrome (GBS) within 6 weeks of receipt of a previous dose of flu vaccine without another cause being identified.

Common side effects:

- May cause mild influenza symptoms including runny nose, nasal congestion, cough, sore throat, fever.
- Some children may have a headache, decreased appetite or weakness

Administering FluMist®[3]



Dosage:

- FluMist is administered via the intranasal (ITN) route. The dosage is 0.2 mL (0.1 mL in each nostril).
- Children 9 years of age and older need 1 dose of vaccine.
- Children 2 to 8 years of age who have never received a seasonal influenza vaccine need 2 doses administered at least one month apart.